Format

Send to

Choose Destination
Oncotarget. 2016 Nov 29;7(48):79584-79595. doi: 10.18632/oncotarget.12861.

MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.

Author information

1
Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, People's Republic of China.
2
Department of Neurology, Institute of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, People's Republic of China.
3
Department of Medicine, Shangqiu Medical School, Shangqiu 476000, Henan Province, People's Republic of China.
4
Department of Clinical Medicine, Shaoyang Medical College, Shaoyang 422000, Hunan Province, People's Republic of China.

Abstract

Glioblastoma multiforme (GBM) is a chemotherapy-resistant brain tumor with limited treatment options. Temozolomide (TMZ), an alkylating agent, is a front-line chemotherapeutic drug currently employed in GBM. Although it is currently the most promising chemotherapy for GBM, resistance to TMZ is also common and accounts for many treatment failures. Therefore, understanding the underlying mechanisms that generate resistance is essential to develop more effective chemotherapies. Here, we show that microRNA-101 (miR-101) was significantly downregulated in TMZ-resistant GBM cells and human specimens. Instead, over-expression of miR-101 could sensitize resistant GBM cells to TMZ through downregulation of glycogen synthase kinase 3β (GSK3β). Moreover, we found that GSK3β inhibition could enhance TMZ effect through repression of MGMT via promoter methylation. Importantly, decreased expression of miR-101 is related to poor prognosis in patients with GBM, suggesting its potential role as a new prognostic marker in GBM. In conclusion, our study demonstrates that miR-101 can reverse TMZ resistance by inhibition of GSK3β in GBM, thus offer a novel and powerful strategy for GBM therapy.

KEYWORDS:

chemoresistance; glioblastoma; microRNA; prognosis; temozolomide

PMID:
27792996
PMCID:
PMC5346737
DOI:
10.18632/oncotarget.12861
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center